

# CELLDEX THERAPEUTICS, INC.

Filed by  
**FMR LLC**

## **FORM SC 13G/A** (Amended Statement of Ownership)

Filed 02/14/17

Address	53 FRONTAGE ROAD SUITE 220 HAMPTON, NJ 08827
Telephone	908-200-7500
CIK	0000744218
Symbol	CLDX
SIC Code	2835 - In Vitro and In Vivo Diagnostic Substances
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**SCHEDULE 13G**

**Amendment No. 4  
CELLDEX THERAPEUTICS INC NEW  
COMMON STOCK**

Cusip #15117B103

Check the appropriate box to designate the rule pursuant to which this

Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Cusip #15117B103

Item 1: Reporting Person - FMR LLC Item 2: (a)

(b)  Item 4: Delaware Item 5: 1,911,665 Item 6: 0 Item 7: 19,330,211 Item 8: 0 Item 9: 19,330,211 Item 11: 16.174% Item 12: HC Cusip #15117B103 Item 1:  
Reporting Person - Abigail P. Johnson Item 2: (a)

(b)  Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 19,330,211 Item 8: 0 Item 9: 19,330,211 Item 11: 16.174% Item 12: IN Cusip #15117B103

Item 1: Reporting Person - Select Biotechnology Portfolio Item 2: (a)

(b)  Item 4: Massachusetts Item 5: 7,827,066 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 7,827,066 Item 11: 6.549% Item 12: IV

**Item 1(a). Name of Issuer:**

**CELLDEX THERAPEUTICS INC NEW**

**Item 1(b). Address of Issuer's Principal Executive Offices:**

**53 FRONTAGE ROAD**

**SUITE 220**

**HAMPTON, NJ 08827**

**USA**

**Item 2(a). Name of Person Filing:**

**FMR LLC**

**Item 2(b). Address or Principal Business Office or, if None,  
Residence:**

245 Summer Street, Boston, Massachusetts 02210

**Item 2(c). Citizenship:**

Not applicable

**Item 2(d). Title of Class of Securities:**

**COMMON STOCK**

**Item 2(e). CUSIP Number:**

**15117B103**

**Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b)**

or (c) and the

person filing, FMR LLC, is a parent holding company in accordance with  
Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A).

**Item 4. Ownership**

(a) Amount Beneficially Owned: 19,330,211

(b) Percent of Class: 16.174%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

1,911,665

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the  
disposition of: 19,330,211

disposition of: 0 (iv) shared power to dispose or to direct the

**Item 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CELLDX THERAPEUTICS INC NEW. No one other person's interest in the COMMON STOCK of CELLDX THERAPEUTICS INC NEW is more than five percent of the total outstanding COMMON STOCK.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

See attached Exhibit A.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certifications.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 13, 2017

Date

*/s/ Marc R. Bryant  
Signature*

*Marc R. Bryant  
Duly authorized under Power of Attorney effective as of September 23,  
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries\**

\* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: 0000315066-16-005935

**Exhibit A**

Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

Entity ITEM 3 Classification  
Fidelity Institutional Asset Management Trust Company BK  
**FMR CO., INC \* IA**

\* Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.

Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.

Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company ("FMR Co"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. Fidelity Management & Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees.

This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

**RULE 13d-1(k)(1) AGREEMENT**

The undersigned persons, on February 13, 2017, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CELLEX THERAPEUTICS INC NEW at December 30, 2016.

**FMR LLC**

*By /s/ Marc R. Bryant  
Marc R. Bryant  
Duly authorized under Power of Attorney effective as of September 23,  
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries\**

**Abigail P. Johnson**

*By /s/ Marc R. Bryant  
Marc R. Bryant  
Duly authorized under Power of Attorney effective as of December 16,  
2015, by and on behalf of Abigail P. Johnson\**

**Select Biotechnology Portfolio**

*By /s/ Marc R. Bryant  
Marc R. Bryant  
Secretary*

\* This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on June 10, 2016, accession number: 0000315066-16-005935